<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00380393</url>
  </required_header>
  <id_info>
    <org_study_id>106464</org_study_id>
    <nct_id>NCT00380393</nct_id>
  </id_info>
  <brief_title>Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.</brief_title>
  <official_title>A Study of the Efficacy Against Episodes of Clinical Malaria Due to P. Falciparum Infection of GSK Biologicals Candidate Vaccine RTS,S/AS01, Administered According to a 0,1,2-months Schedule in Children Aged 5 to 17 Months Living in Tanzania &amp; Kenya</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This phase IIb trial is being done to find out if the RTS,S/AS01 vaccine helps to prevent
      children from falling ill with malaria and to evaluate vaccine safety.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 3, 2007</start_date>
  <completion_date type="Actual">November 11, 2008</completion_date>
  <primary_completion_date type="Actual">August 15, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First case of malaria meeting the primary case definition</measure>
    <time_frame>Over a period starting 14 days after Dose 3 and extending for 4 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>First case of malaria meeting the secondary case definition.</measure>
    <time_frame>Over a period starting 14 days after Dose 3 and extending for 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple events of malaria meeting the primary case definition.</measure>
    <time_frame>Over a period starting 14 days after Dose 3 and extending for 4 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple events of malaria meeting the secondary case definition.</measure>
    <time_frame>Over a period starting 14 days after Dose 3 and extending for 4 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite prevalence and density</measure>
    <time_frame>At 4½ months post Dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin</measure>
    <time_frame>At 4½ months post Dose 3.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited symptoms and local reactions.</measure>
    <time_frame>Over a 7-day follow-up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited symptoms.</measure>
    <time_frame>Over a 30-day follow-up period (day of vaccination and 29 subsequent days) after each vaccination.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>From the time of first vaccination (Month 0) until 4½ months post Dose 3 (Month 6½).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of parameters of hematological monitoring outside acceptable ranges.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody to the P. falciparum circumsporozoite (CS) repeat domain (anti-CS antibody) titers.</measure>
    <time_frame>Prior to vaccination, 1 month post Dose 3 and 4½ months post Dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-hepatitis B surface antigen (anti-HBs) titers</measure>
    <time_frame>Prior to vaccination and 1 month post Dose 3.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of CD4+ and CD8+ CS-specific T-cells expressing at least 2 of the following: IL-2, CD40L, TNF-α and IFN-у.</measure>
    <time_frame>Prior to vaccination and 1 month post Dose 3.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">855</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK malaria vaccine 257049 Vaccine</intervention_name>
    <description>3 dose intramuscular injection</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>RTS</other_name>
    <other_name>S/AS01E vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine</intervention_name>
    <description>3 dose intramuscular injection</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female child of between 5 months and 17 months of age at the time of first
             vaccination.

          -  Written or oral, signed or thumb-printed and witnessed informed consent obtained from
             the parent(s)/guardian(s) of the child..

          -  Subjects who the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol.

        Exclusion Criteria:

          -  Acute disease at the time of enrolment.

          -  Serious acute or chronic illness determined by clinical or physical examination and
             laboratory screening tests.

          -  Laboratory screening tests for haemoglobin, total white cell count, platelets, ALT and
             creatinine out of acceptable limits.

          -  Planned administration/administration of a vaccine not foreseen by the study within 30
             days of the first dose of vaccine(s) with the exception of tetanus toxoid or scheduled
             diphtheria, pertussis or measles vaccine.

          -  Use of any investigational or non-registered drug or vaccine within 30 days preceding
             the first dose of study vaccine, or planned use during the study period.

          -  Administration of immunoglobulins, blood transfusions or other blood products within
             the three months preceding the first dose of study vaccine or planned administration
             during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within 6 months prior to the first vaccine dose

          -  Previous participation in any other malaria vaccine trial.

          -  Simultaneous participation in any other clinical trial.

          -  Same sex twin.

          -  History of allergic reactions (significant IgE-mediated events) or anaphylaxis to
             previous immunizations.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Any other findings that the investigator feels would increase the risk of having an
             adverse outcome from participation in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Months</minimum_age>
    <maximum_age>17 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kilifi</city>
        <zip>80108</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amani, Tanga</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Tanzania</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois MC, Demoitié MA, Stallaert JF, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, von Seidlein L. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med. 2008 Dec 11;359(24):2521-32. doi: 10.1056/NEJMoa0807381. Epub 2008 Dec 8.</citation>
    <PMID>19064627</PMID>
  </reference>
  <reference>
    <citation>Lang TA, Gould J, von Seidlein L, Lusingu JP, Mshamu S, Ismael S, Liheluka E, Kamuya D, Mwachiro D, Olotu A, Njuguna P, Bejon P, Marsh V, Molyneux C. Approaching the community about screening children for a multicentre malaria vaccine trial. Int Health. 2012 Mar;4(1):47-54. doi: 10.1016/j.inhe.2011.10.003.</citation>
    <PMID>24030880</PMID>
  </reference>
  <reference>
    <citation>Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Olivier A, Benns S, Olomi R, Msham S, Lang T, Gould J, Hallez K, Guerra Y, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Dekker D, Malle L, Ismael S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, Bejon P, von Seidlein L. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. PLoS One. 2010 Nov 29;5(11):e14090. doi: 10.1371/journal.pone.0014090. Erratum in: PLoS One. 2010; 5(12) doi: 10.1371/annotation/3b62fdef-4cdd-40cc-b69d-69afd2000c4f. PLoS One. 2010;5(12) doi: 10.1371/annotation/0543a689-83a6-4528-92a1-a0f978b47fcb.</citation>
    <PMID>21124768</PMID>
  </reference>
  <reference>
    <citation>Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang T, Gould J, Dubois MC, Jongert E, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Lapierre D, Ballou WR, Cohen J, Lemnge MM, Peshu N, Marsh K, Riley EM, von Seidlein L, Bejon P. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis. 2011 Feb;11(2):102-9. doi: 10.1016/S1473-3099(10)70262-0. Epub 2011 Jan 13. Erratum in: Lancet Infect Dis. 2011 Mar;11(3):159.</citation>
    <PMID>21237715</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2006</study_first_submitted>
  <study_first_submitted_qc>September 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2006</study_first_posted>
  <disposition_first_submitted>September 3, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 3, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 4, 2009</disposition_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>Plasmodium</keyword>
  <keyword>RTS</keyword>
  <keyword>S/AS01</keyword>
  <keyword>Falciparum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>106464</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106464</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106464</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106464</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106464</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106464</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <pending_results>
    <submitted>August 25, 2017</submitted>
    <returned>September 20, 2017</returned>
    <submitted>November 10, 2017</submitted>
    <returned>December 11, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

